Program - Japanese Safety Pharmacology Society

Program

13th Japanese Safety Pharmacology Society Annual Meeting Program (as of January 20, 2022)
Online viewing period
- Live streaming period: February 4 (Fri) - 5 (Sat), 2022
- On-demand viewing period: February 4 (Fri) - March 18 (Fri), 2022
President: Atsushi Fujiwara (Ina Research Inc.)

Day 1: Friday, Feb. 4
Day 2: Saturday, Feb. 5

Day 1: Friday, Feb. 4

All day	Poster Sessions <On-demand streaming>
9:00 〜	Opening Atsushi Fujiwara (President of 13th Annual Meeting)
9:10～10:55	Symposium I: Cardiovascular System <Live streaming> Current challenges and future perspectives of safety pharmacology testing using new approach methodologies Yasunari Kanda (National Institute of Health Sciences) ICH S7B Q&A: Best practice for in vivo QT assay Katsuyoshi Chiba (Daiichi Sankyo Co., Ltd.) ICH S7B Q&A: Best practice for in vitro assay Takashi Yoshinaga (Eisai Co., Ltd.) Panel discussions
11:25 〜 12:25	Poster presentation <Live streaming>
13:20 ～ 14:30	Sponsored Session 1<Live streaming> Zebrafish Role in Pharmacological Safety and Human Health Risks - New approaches for enhancing bio-pharmacological screening: from bench to bedside Daniel Caballero-Díaz (ZeClinics) Ina Research Inc. Retrieving data from PharmaPendium in order to determine first-in-human doses Takahiro Ohyama (Elsevier Japan K.K.) Elsevier Japan K.K.
15:00 〜 16:45	Symposium 2: Central Nervous System <Live streaming> Cutting-edge drug dependence evaluation Present drug abuse situation in Japan Tsutomu Suzuki (Department of Pharmacology, Faculty of Pharmacy, Shonan University of Medical Sciences) Evaluation of the adverse effects of new psychoactive substances: dependence and toxicity Masahiko Funada (National Institute of Mental Health, National Center of Neurology and Psychiatry) Distress during the morphine withdrawal: Behavioral and cellular analysis Tomohisa Mori (Department of Pharmacology, Hoshi University)

Day 2: Saturday, Feb. 5

All day	Poster Sessions <On-demand streaming>
8:20～8:55	Sponsored Session 2 <Live streaming> Human Cardiomyocytes and Spinal Cord Cultures for Cardiotoxicity and Neurotoxicity Risk Assessment Najah ABI-GERGES (AnaBios Corporation) AnaBios Corporation
9:05 ～ 10:25	Invited Lecture<Recorded presentation> To predict drug-induced cardiac toxicity by using weighted gene co-expression net-work analysis Jufeng Wang (Pharmaron, Beijing, China） What we should include in study reports about how the QT interval is measured; precision, accuracy, or both Brian Roche (Charles River Laboratories, Executive Director, Global Safety Pharmacology)
10:50-11:50	Poster presentation <Live streaming>
12:20~13:30	Sponsored Session 3<Live streaming> ICH S1B(R1): ADDENDUM TO THE GUIDELINE ON TESTING FOR CARCINOGENICITY OF PHARMACEUTICALS -- Suggestion of in vitro molecular targeted panel assay approach -- Masami Tamaoka, Makoto Imatachi (Eurofins Discovery, Japan) Eurofins Discovery, Japan MEA Measurement in Human Brain Organids ：Analysis using Low Frequency Componets Ikuro Suzuki (Tohoku Institute of Technology) SCREEN Holdings Co., Ltd/Alpha MED Scientific Inc.
14:00～15:30	Workshop <Live streaming> Safety pharmacology & SEND: Status and challenges Current Situation of SEND Conversion for Safety Pharmacology Studies Shin-ichi Horikawa (Ina Research Inc.) Example of SEND Implementation in Pharmaceutical Company -Creation of SEND Datasets for Safety Pharmacology studies- Izumi Matsumoto (Sumitomo Dainippon Pharma Co., Ltd.) Outsource the conversion of safety pharmacological tests to SEND Fumio Masaki (CMIC Pharma Science Co., Ltd.)
16:00～16:40	Special Lecture <Live streaming> Uterus transplantation: from basic research toward future clinical application Iori Kisu(Department of Obstetrics and Gynecology, Keio University School of Medicine)
16:40～	Closing <Live streaming> Closing Remarks Atsushi Fujiwara (President of 13^th Annual Meeting) Harushige Ozaki (President of 14^th Annual Meeting)